αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer

Clinical and Experimental Metastasis

Volumn 31, Issue 7, 2014, Pages 841-851

  Berghoff, Anna Sophie ^a,b,c   Kovanda, Astrid Kerstin ^b,c   Melchardt, Thomas ^d   Bartsch, Rupert ^b,c   Hainfellner, Johannes A ^a,c   Sipos, Bence ^e   Schittenhelm, Jens ^e   Zielinski, Christoph C ^b,c   Widhalm, Georg ^b,c   Dieckmann, Karin ^b,c   Weller, Michael ^f   Goodman, Simon L ^g   Birner, Peter ^b,c   Preusser, Matthias ^b,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Austrian Breast and Colorectal Cancer Study Group   (Austria)

^d PARACELSUS MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g MERCK KGAA   (Germany)

Author keywords

Brain metastases; Integrins; Non small cell lung cancer; Survival

Indexed keywords

ALPHA V BETA 3 INTEGRIN; ALPHA V BETA 5 INTEGRIN; ALPHA V BETA 6 INTEGRIN; BETA3 INTEGRIN; BETA5 INTEGRIN; BETA6 INTEGRIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; UNCLASSIFIED DRUG; ALPHAVBETA5 INTEGRIN; ALPHAVBETA6 INTEGRIN; INTEGRIN; TUMOR ANTIGEN; VITRONECTIN RECEPTOR;

ARTICLE; BRAIN METASTASIS; CANCER SURVIVAL; CELL MEMBRANE; CLINICAL STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON SMALL CELL LUNG CANCER; PRIMARY TUMOR; PROTEIN EXPRESSION; SMALL CELL LUNG CANCER; BRAIN TUMOR; LUNG TUMOR; METABOLISM; PATHOLOGY; SECONDARY;

ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; INTEGRINS; LUNG NEOPLASMS; MALE; RECEPTORS, VITRONECTIN;

EID: 84910146521     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-014-9675-0     Document Type: Article

References (52)

1. Ahmed N, Riley C, Rice GE, Quinn MA, Baker MS (2002) Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. J Histochem Cytochem 50(10):1371–1380
2. Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B (2006) Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 65(5):1536–1543. doi:10.1016/j.ijrobp.2006.04.036
3. Bauerle T, Komljenovic D, Merz M, Berger MR, Goodman SL, Semmler W (2011) Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer 128(10):2453–2462. doi:10.1002/ijc.25563
4. Bender R, Lange S (2001) Adjusting for multiple testing–when and how? J Clin Epidemiol 54(4):343–349
5. Berghoff AS, Ilhan-Mutlu A, Wohrer A, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Melchardt T, Dome B, Heinzl H, Birner P, Preusser M (2014) Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases. Strahlenther Onkol. doi:10.1007/s00066-014-0639-8
6. Berghoff AS, Rajky O, Winkler F, Bartsch R, Furtner J, Hainfellner JA, Goodman SL, Weller M, Schittenhelm J, Preusser M (2013) Invasion patterns in brain metastases of solid cancers. Neuro Oncol 15(12):1664–1672. doi:10.1093/neuonc/not112
7. Birner P, Beer A, Vinatzer U, Stary S, Hoftberger R, Nirtl N, Wrba F, Streubel B, Schoppmann SF (2012) MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1. Clin Cancer Res 18 (7):1879–1887. doi:10.1158/1078-0432.CCR-11-2364
8. Boger C, Kalthoff H, Goodman SL, Behrens HM, Rocken C (2014) Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression. Virchows Arch 464(1):69–78. doi:10.1007/s00428-013-1506-1
9. Brozovic A, Majhen D, Roje V, Mikac N, Jakopec S, Fritz G, Osmak M, Ambriovic-Ristov A (2008) alpha(v)beta(3) Integrin-mediated drug resistance in human laryngeal carcinoma cells is caused by glutathione-dependent elimination of drug-induced reactive oxidative species. Mol Pharmacol 74(1):298–306. doi:10.1124/mol.107.043836
10. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97(9):643–655. doi:10.1093/jnci/dji112
11. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9–22. doi:10.1038/nrc2748
12. Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ, Wistuba II, Roth JA, McGuire MJ, Brown KC (2007) A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res 67(12):5889–5895. doi:10.1158/0008-5472.CAN-07-0245
13. Enns A, Korb T, Schluter K, Gassmann P, Spiegel HU, Senninger N, Mitjans F, Haier J (2005) Alphavbeta5-integrins mediate early steps of metastasis formation. Eur J Cancer 41(7):1065–1072. doi:10.1016/j.ejca.2004.12.031
14. Fidler IJ (2011) The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 21(2):107–112. doi:10.1016/j.semcancer.2010.12.009
15. Gladson CL (1996) Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol 55(11):1143–1149
16. Goldberg I, Davidson B, Reich R, Gotlieb WH, Ben-Baruch G, Bryne M, Berner A, Nesland JM, Kopolovic J (2001) Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Clin Cancer Res 7(12):4073–4079
17. Goodman SL, Grote HJ, Wilm C (2012) Matched rabbit monoclonal antibodies against alphav-series integrins reveal a novel alphavbeta3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biol Open 1(4):329–340. doi:10.1242/bio.2012364
18. Goodman SL, Picard M (2012) Integrins as therapeutic targets. Trends Pharmacol Sci 33(7):405–412. doi:10.1016/j.tips.2012.04.002
19. Guo S, Reddy CA, Chao ST, Suh JH, Barnett GH, Vogelbaum MA, Videtic GM (2012) Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases. Lung Cancer 77(2):389–393. doi:10.1016/j.lungcan.2012.03.028
20. Hazelbag S, Kenter GG, Gorter A, Dreef EJ, Koopman LA, Violette SM, Weinreb PH, Fleuren GJ (2007) Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol 212(3):316–324. doi:10.1002/path.2168
21. Hehlgans S, Haase M, Cordes N (2007) Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 1775(1):163–180. doi:10.1016/j.bbcan.2006.09.001
22. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21(20):3798–3807. doi:10.1200/JCO.2003.11.069
23. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110(6):673–687
24. Kageshita T, Hamby CV, Hirai S, Kimura T, Ono T, Ferrone S (2000) Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis. Cancer Immunol Immunother 49(6):314–318
25. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844–847
26. Kuremsky JG, Urbanic JJ, Petty WJ, Lovato JF, Bourland JD, Tatter SB, Ellis TL, McMullen KP, Shaw EG, Chan MD (2013) Tumor histology predicts patterns of failure and survival in patients with brain metastases from lung cancer treated with gamma knife radiosurgery. Neurosurgery 73(4):641–647; discussion 647. doi:10.1227/NEU.0000000000000072
27. Lautenschlaeger T, Perry J, Peereboom D, Li B, Ibrahim A, Huebner A, Meng W, White J, Chakravarti A (2013) In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines. Radiat Oncol 8:246. doi:10.1186/1748-717X-8-246
28. Lorger M, Krueger JS, O’Neal M, Staflin K, Felding-Habermann B (2009) Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci USA 106(26):10666–10671. doi:10.1073/pnas.0903035106
29. Manegold C, Vansteenkiste J, Cardenal F, Schuette W, Woll PJ, Ulsperger E, Kerber A, Eckmayr J, von Pawel J (2013) Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Invest New Drugs 31(1):175–182. doi:10.1007/s10637-012-9842-6
30. Massabeau C, Rouquette I, Lauwers-Cances V, Mazieres J, Bachaud JM, Armand JP, Delisle MB, Favre G, Toulas C, Cohen-Jonathan-Moyal E (2009) Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 75(3):696–702. doi:10.1016/j.ijrobp.2008.11.050
31. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D, Neuteboom B, Goodman SL (2009) Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 124(11):2719–2727. doi:10.1002/ijc.24240
32. Mittelbronn M, Warth A, Meyermann R, Goodman S, Weller M (2012) Expression of integrins alphavbeta3 and alphavbeta5 and their ligands in primary and secondary central nervous system neoplasms. Histol Histopathol 33:405–412
33. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Heino J, Pyrhonen S (2004) Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma. Melanoma Res 14(1):29–37
34. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Marosi C, Zielinski C, Mehta MP, Winkler F, Wick W, von Deimling A (2012) Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 123(2):205–222. doi:10.1007/s00401-011-0933-9
35. Preusser M, Winkler F, Collette L, Haller S, Marreaud S, Soffietti R, Klein M, Reijneveld JC, Tonn JC, Baumert BG, Mulvenna P, Schadendorf D, Duchnowska R, Berghoff AS, Lin N, Cameron DA, Belkacemi Y, Jassem J, Weber DC (2012) Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur J Cancer 48(18):3439–3447. doi:10.1016/j.ejca.2012.07.002
36. Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, Brown KC, Bekele BN, Moran C, Wistuba II (2009) Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 22(5):668–678. doi:10.1038/modpathol.2009.19
37. Ramos DM, But M, Regezi J, Schmidt BL, Atakilit A, Dang D, Ellis D, Jordan R, Li X (2002) Expression of integrin beta 6 enhances invasive behavior in oral squamous cell carcinoma. Matrix biology: journal of the International Society for Matrix Biology 21(3):297–307
38. Ruegg C, Monnier Y, Kuonen F, Imaizumi N (2011) Radiation-induced modifications of the tumor microenvironment promote metastasis. Bull Cancer 98(6):47–57. doi:10.1684/bdc.2011.1372
39. Schittenhelm J, Schwab EI, Sperveslage J, Tatagiba M, Meyermann R, Fend F, Goodman SL, Sipos B (2013) Longitudinal expression analysis of alphav integrins in human gliomas reveals upregulation of Integrin alphavbeta3 as a negative prognostic factor. J Neuropathol Exp Neurol 72(3):194–210. doi:10.1097/NEN.0b013e3182851019
40. Schittenhelm J, Klein A, Tatagiba MS, Meyermann R, Fend F, Goodman SL, Sipos B (2013) Comparing the expression of integrins alphavbeta3, alphavbeta5, alphavbeta6, alphavbeta8, fibronectin and fibrinogen in human brain metastases and their corresponding primary tumors. Int J Clin Exp Pathol 6(12):2719–2732
41. Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, Grau SJ, Thon N, Goetz C, Kretzschmar HA, Tonn JC, Goldbrunner RH (2008) Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 18(3):378–386. doi:10.1111/j.1750-3639.2008.00137.x
42. Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, Cohen-Jonathan Moyal E (2009) Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res 69(8):3308–3316. doi:10.1158/0008-5472.CAN-08-2158
43. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30(4):419–425. doi:10.1200/JCO.2011.38.0527
44. Tchaicha JH, Mobley AK, Hossain MG, Aldape KD, McCarty JH (2010) A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis. Oncogene 29(31):4460–4472. doi:10.1038/onc.2010.199
45. Vellon L, Menendez JA, Lupu R (2005) AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene 24(23):3759–3773. doi:10.1038/sj.onc.1208452
46. Vogetseder A, Thies S, Ingold B, Roth P, Weller M, Schraml P, Goodman SL, Moch H (2013) alphav-Integrin isoform expression in primary human tumors and brain metastases. Int J Cancer 133(10):2362–2371. doi:10.1002/ijc.28267
47. Woehrer A (2013) Brain tumor epidemiology in Austria and the Austrian Brain Tumor Registry. Clin Neuropathol 32(4):269–285. doi:10.5414/NP300600
48. Wohrer A, Waldhor T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mosenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rossler K, Hainfellner JA (2009) The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 95(3):401–411. doi:10.1007/s11060-009-9938-9
49. Wu YJ, Muldoon LL, Gahramanov S, Kraemer DF, Marshall DJ, Neuwelt EA (2012) Targeting alphaV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model. J Neurooncol 110(1):27–36. doi:10.1007/s11060-012-0942-0
50. Yamanaka R (2009) Medical management of brain metastases from lung cancer (review). Oncol Rep 22(6):1269–1276
51. Zhang ZY, Xu KS, Wang JS, Yang GY, Wang W, Wang JY, Niu WB, Liu EY, Mi YT, Niu J (2008) Integrin alphanvbeta6 acts as a prognostic indicator in gastric carcinoma. Clin Oncol (R Coll Radiol) 20(1):61–66. doi:10.1016/j.clon.2007.09.008
52. Zutter MM (2007) Integrin-mediated adhesion: tipping the balance between chemosensitivity and chemoresistance. Adv Exp Med Biol 608:87–100